FVIII Mimetics in Hemophilia: Comparing Emicizumab, Mim8, and NXT007 – Key Insights from BIC Meeting
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, posted on LinkedIn:
”FVIII mimetics – How different are these products? Fascinating insights from Peter Lenting at the BIC meeting on the evolving landscape of FVIII-mimetic therapies․
Emicizumab – The established pioneer with proven clinical efficacy, stimulating FIXa activity ~10-fold less than FVIIIa but effectively promoting thrombin generation and fibrin formation
Mim8 – Next-generation optimization with >20,000-fold increase in FIXa proteolytic activity and 15-fold higher potency vs emicizumab in vitro
NXT007 – Enhanced affinity through novel light chain engineering, showing 30-40 fold higher affinity for FX/FXa with improved ternary complex formation
Different epitopes, different mechanisms: While all target the FIXa-FX interaction, each product has unique binding sites and kinetic properties. Mim8’s distinct epitope includes loop 333-338 (FVIIIa binding site), potentially explaining its enhanced cofactor activity.
Clinical implications beyond haemophilia A: FVIII mimetics show promise for various bleeding disorders:
– Acquired hemophilia A – bypassing FVIII inhibitors effectively
– Type 3 von Willebrand disease – addressing the associated FVIII deficiency component
– Patients with alloantibodies to VWF or FVIII
Note: Inno8 was not part of this session, as this innovative oral development was presented in a dedicated session earlier at the meeting by Jan Astermark.”

Stay updated with Hemostasis Today.
-
Nov 19, 2025, 18:03Andres Ricaurte Fajardo on a Strongyloides Stercoralis Hyperinfection with Thrombosis
-
Nov 19, 2025, 17:50Marilena Vrana Reflects on PPTA Europe’s Visits with Members and Stakeholders in 2025
-
Nov 19, 2025, 17:32Michael Makris Shares Insights from Global Forum Meeting of the WFH Meeting in Montreal
-
Nov 19, 2025, 17:14Yazan Abou Ismail Takes The Legacy Award from Qatar Foundation
-
Nov 19, 2025, 17:02Wolfgang Miesbach Shares Real-World Evidence on Eptacog Beta from Spain
-
Nov 19, 2025, 16:34Ishita Singh Reflects on Haematocon 2025: A Reminder of Her Commitment to The Journey
-
Nov 19, 2025, 16:23Mehdi Kashani: I’m Really Excited to Share Schistosite.com
-
Nov 19, 2025, 16:09A ”Meow-cyte” from Melaku Abay Muluneh or Why Microscopy Never Gets Old!
-
Nov 19, 2025, 15:56Cuilan Li on her Contribution to a Cutting-Edge Project in Polycythemia Vera
